These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12419164)

  • 1. Development and identification of monoclonal antibodies against c-erbB-2 p185 intracellular domain.
    Qu P; Zhang W; Cao D; Huang X; Wang H; Li M; Tian H
    Zhonghua Bing Li Xue Za Zhi; 2002 Apr; 31(2):148-50. PubMed ID: 12419164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer.
    Dean CJ; Eccles SA; Valeri M; Box G; Allan S; McFarlane C; Sandle J; Styles J
    Cell Biophys; 1993; 22(1-3):111-27. PubMed ID: 7534210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
    Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
    Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
    DiGiovanna MP; Stern DF
    Cancer Res; 1995 May; 55(9):1946-55. PubMed ID: 7728765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Preparation and characterization of specific monoclonal antibodies against HER2].
    Liu HQ; Wang DM; Qu H; Shi L; Huang LH; Feng CL; Zhang LY; Zhu WB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 May; 26(5):456-8. PubMed ID: 20423652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
    Meenakshi A; Kumar RS; Kumar NS
    Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin.
    Xu FJ; Boyer CM; Bae DS; Wu S; Greenwald M; O'Briant K; Yu YH; Mills GB; Bast RC
    Int J Cancer; 1994 Oct; 59(2):242-7. PubMed ID: 7927925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185.
    Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC
    Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185.
    Meenakshi A; Kumar RS; Ganesh V; Sivakumar N
    Hum Antibodies; 2003; 12(4):123-7. PubMed ID: 15156100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of new HER2 monoclonal antibodies.
    Vasconcellos FA; Aleixo PB; Stone SC; Conceição FR; Dellagostin OA; Aleixo JA
    Acta Histochem; 2013 Apr; 115(3):240-4. PubMed ID: 22901624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preparation of monoclonal antibody against human c-erbB2 and identification of its specificity].
    Song SX; Li MY; Hou ZH; Liu FY; Lu ZJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):319-21. PubMed ID: 15862149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK; Mann E; Elliger SS; Dugger TC; Arteaga CL
    Cancer Res; 1994 Mar; 54(5):1367-73. PubMed ID: 7907001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
    Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
    Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
    Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-erbB-2/p185-directed therapy in human lung adenocarcinoma.
    Snider JM; Bushnell LJ; Chen LC; Lanza LA
    Ann Thorac Surg; 1996 Nov; 62(5):1454-9. PubMed ID: 8893583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.